Biotech · Private company
Dermira, Inc.
Track this companyFree. Adds Dermira, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials132 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- Olumacostat Glasaretil Gel, 5.0%Phase 3 · Acne VulgarisClinicalTrials.gov · fetched Nov 12, 2026
- Olumacostat Glasaretil Gel, VehiclePhase 3 · Acne VulgarisClinicalTrials.gov · fetched Nov 12, 2026
- Olumacostat GlasaretilPhase 2 · Acne VulgarisClinicalTrials.gov · fetched Nov 12, 2026
- VehiclePhase 2 · Acne VulgarisClinicalTrials.gov · fetched Nov 12, 2026
- Red Light (PDT)Phase 1 · Acne VulgarisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- Lebrikizumab in Moderate-to-severe Atopic DermatitisPHASE4 · ACTIVE_NOT_RECRUITING · started Jul 2, 2025ClinicalTrials.gov NCT06906497 · fetched Nov 12, 2026
- A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 18, 2022ClinicalTrials.gov NCT05559359 · fetched Nov 12, 2026
- Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)PHASE3 · COMPLETED · started Jun 15, 2020ClinicalTrials.gov NCT04392154 · fetched Nov 12, 2026
- Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic DermatitisPHASE3 · COMPLETED · started Feb 11, 2020ClinicalTrials.gov NCT04250350 · fetched Nov 12, 2026
- Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.PHASE3 · COMPLETED · started Feb 3, 2020ClinicalTrials.gov NCT04250337 · fetched Nov 12, 2026
- Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic DermatitisPHASE3 · COMPLETED · started Oct 29, 2019ClinicalTrials.gov NCT04178967 · fetched Nov 12, 2026
- Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)PHASE3 · COMPLETED · started Sep 24, 2019ClinicalTrials.gov NCT04146363 · fetched Nov 12, 2026
- A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic DermatitisPHASE2 · COMPLETED · started Jan 30, 2018ClinicalTrials.gov NCT03443024 · fetched Nov 12, 2026
- A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne VulgarisPHASE3 · COMPLETED · started Mar 21, 2017ClinicalTrials.gov NCT03127956 · fetched Nov 12, 2026
- A Study of Olumacostat Glasaretil Gel in Subjects With Acne VulgarisPHASE3 · COMPLETED · started Feb 6, 2017ClinicalTrials.gov NCT03073486 · fetched Nov 12, 2026
- A Study of Olumacostat Glasaretil Gel in Subjects With Acne VulgarisPHASE3 · COMPLETED · started Dec 27, 2016ClinicalTrials.gov NCT03028363 · fetched Nov 12, 2026
- A Dose-ranging Study of DRM01 in Subjects With Acne VulgarisPHASE2 · COMPLETED · started Apr 1, 2015ClinicalTrials.gov NCT02431052 · fetched Nov 12, 2026
- Open-label Safety and Tolerability Study of LTS-PDT in Healthy VolunteersPHASE1 · COMPLETED · started Apr 1, 2013ClinicalTrials.gov NCT01830764 · fetched Nov 12, 2026